Crossmark

Effects of pemafibrate (a selective PPAR-α agonist) versus weight loss through an intensive lifestyle modification on liver enzymes, serum soluble dipeptidyl peptidase-4, and hepatic steatosis and fibrosis evaluated by FibroScan transient elastography in people with type 2 diabetes and MASLD

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2025.100839

Published Print: 2025-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Kato, Kanako https://orcid.org/0009-0008-3639-5100
Jojima, Teruo https://orcid.org/0000-0002-2907-261X
Tanuma, Dai https://orcid.org/0009-0004-6878-9981
Suda, Kanako https://orcid.org/0009-0009-7740-1543
Sakurai, Shintaro https://orcid.org/0009-0003-9689-9363
Iijima, Toshie https://orcid.org/0000-0002-4613-3744
Tomaru, Takuya https://orcid.org/0000-0003-0850-5655
Usui, Isao https://orcid.org/0000-0002-4720-4882
Aso, Yoshimasa https://orcid.org/0000-0003-0610-1999
License Information

Text and Data Mining valid from 2025-01-01

Text and Data Mining valid from 2025-01-01

Version of Record valid from 2025-11-05
More Information

This article is maintained by: Elsevier

Article Title: Effects of pemafibrate (a selective PPAR-α agonist) versus weight loss through an intensive lifestyle modification on liver enzymes, serum soluble dipeptidyl peptidase-4, and hepatic steatosis and fibrosis evaluated by FibroScan transient elastography in people with type 2 diabetes and MASLD

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2025.100839

Content Type: article

Copyright: © 2025 HCFMUSP. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below